Farshid Siadat, MD, FRCPC (@fsiadat) 's Twitter Profile
Farshid Siadat, MD, FRCPC

@fsiadat

Genitourinary Pathologist, Site lead AP Rockyview Hospital, Clinical Associate Professor of Pathology. (posts are not medical advice) #gupath #pathologist

ID: 956228349432553473

calendar_today24-01-2018 18:12:59

537 Tweet

1,1K Followers

204 Following

Kiril_T_Can (@kiril_t_can) 's Twitter Profile Photo

Confused with all new kidney tumors? ➡️ Free access to our review paper for 50 days: "Kidney tumors: new and emerging kidney tumor entities" authors.elsevier.com/a/1fvZ5_gfqVL3… Just published in Surgical #Pathology Clinics - book edited by Ming Zhou, MD, PhD #pathtwitter Farshid Siadat, MD, FRCPC #GUPS

Kiril_T_Can (@kiril_t_can) 's Twitter Profile Photo

Just published in European Urology: "European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist’s Point of View" Free link: authors.elsevier.com/c/1g81F14kplrL… #kidney #gupath

GU Pathology Society (GUPS) (@gu_path_society) 's Twitter Profile Photo

GUPS members voiced their opinion on reclassifying Grade Group 1 prostate cancer as non-cancer. 81.7% opposed, 13.8% supported and 4.6% uncertain about, removing the cancer label from GG1 cancer. Read more: authors.elsevier.com/a/1g7zZ3r93nVD…. Thank you all for participating in this survey.

GUPS members voiced their opinion on reclassifying Grade Group 1 prostate cancer as non-cancer. 81.7% opposed, 13.8% supported and 4.6% uncertain about, removing the cancer label from GG1 cancer. Read more: authors.elsevier.com/a/1g7zZ3r93nVD…. Thank you all for participating in this survey.
Mohi Ghofrani, MD, MBA (@mghofrani) 's Twitter Profile Photo

Someone should write a thriller about a pathologist who confesses to murder IN ALL CAPS in the Comment of every pathology report but gets away with it because no one ever reads anything below the Final Diagnosis.

Farshid Siadat, MD, FRCPC (@fsiadat) 's Twitter Profile Photo

Exciting, unexpected opportunity! We have an opening for 2023-2024 #GUPath funded fellowship at one of the largest centralized GU practices in #Canada and North America. Join us in #Calgary and gain valuable experience in a dynamic & challenging field. #Pathology #Fellowship

Farshid Siadat, MD, FRCPC (@fsiadat) 's Twitter Profile Photo

Mixed small cell neuroendocrine carcinoma (SCNEC) and urothelial carcinoma. The presence of a NEC component should alert the clinician to consider the potential role of neoadjuvant/adjuvant chemotherapy. #gupath #bladdercancer

Mixed small cell neuroendocrine carcinoma (SCNEC) and urothelial carcinoma. The presence of a NEC component should alert the clinician to consider the potential role of neoadjuvant/adjuvant chemotherapy.

#gupath #bladdercancer
Miruna Popescu, MD (@mirunapopescu13) 's Twitter Profile Photo

Exceptional speakers panel at the KTF 2024 in Mikulov, Czech Republic. Such a wonderful opportunity to learn & (re)connect with friends and mentors. Bye bye Mikulov! It was a wonderful experience 😊 #PathTwitter

Exceptional speakers panel at the KTF 2024 in Mikulov, Czech Republic.
Such a wonderful opportunity to learn & (re)connect with friends and mentors.
Bye bye Mikulov! It was a wonderful experience 😊
#PathTwitter
USCAP (@theuscap) 's Twitter Profile Photo

USCAP was saddened to learn of the passing of Dr. Christopher D.M. Fletcher. Dr. Fletcher was an exceptional and innovative pathologist who dedicated many years in service to USCAP, including serving as President. He will be missed both personally and professionally.

USCAP was saddened to learn of the passing of Dr. Christopher D.M. Fletcher. Dr. Fletcher was an exceptional and innovative pathologist who dedicated many years in service to USCAP, including serving as President. He will be missed both personally and professionally.